Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection

Anna D. Kosinska; Abdul Moeed; Nina Kallin; Julia Festag; Jinpeng Su; Katja Steiger; Marie Louise Michel; Ulrike Protzer; Percy A. Knolle

doi:10.1038/s41598-019-47149-w

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection

Anna D. Kosinska, Abdul Moeed, Nina Kallin, Julia Festag, Jinpeng Su, Katja Steiger, Marie Louise Michel, Ulrike Protzer, Percy A. Knolle

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Therapeutic vaccination against chronic hepatitis B must overcome high viral antigen load and local regulatory mechanisms that promote immune-tolerance in the liver and curtail hepatitis B virus (HBV)-specific CD8 T cell immunity. Here, we report that therapeutic heterologous HBcore-protein-prime/Modified-Vaccinia-Virus-Ankara (MVA-HBcore) boost vaccination followed by CpG-application augmented vaccine-induced HBcAg-specific CD8 T cell-function in the liver. In HBV-transgenic as well as AAV-HBV-transduced mice with persistent high-level HBV-replication, the combination of therapeutic vaccination with subsequent CpG-application was synergistic to generate more potent HBV-specific CD8 T cell immunity that improved control of hepatocytes replicating HBV.

Original language	English
Article number	10808
Journal	Scientific Reports
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41598-019-47149-w
State	Published - 1 Dec 2019

Access to Document

10.1038/s41598-019-47149-w

Cite this

@article{942c1574de3f408289097fd50619f917,

title = "Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection",

abstract = "Therapeutic vaccination against chronic hepatitis B must overcome high viral antigen load and local regulatory mechanisms that promote immune-tolerance in the liver and curtail hepatitis B virus (HBV)-specific CD8 T cell immunity. Here, we report that therapeutic heterologous HBcore-protein-prime/Modified-Vaccinia-Virus-Ankara (MVA-HBcore) boost vaccination followed by CpG-application augmented vaccine-induced HBcAg-specific CD8 T cell-function in the liver. In HBV-transgenic as well as AAV-HBV-transduced mice with persistent high-level HBV-replication, the combination of therapeutic vaccination with subsequent CpG-application was synergistic to generate more potent HBV-specific CD8 T cell immunity that improved control of hepatocytes replicating HBV.",

author = "Kosinska, {Anna D.} and Abdul Moeed and Nina Kallin and Julia Festag and Jinpeng Su and Katja Steiger and Michel, {Marie Louise} and Ulrike Protzer and Knolle, {Percy A.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41598-019-47149-w",

language = "English",

volume = "9",

journal = "Scientific Reports",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection

AU - Kosinska, Anna D.

AU - Moeed, Abdul

AU - Kallin, Nina

AU - Festag, Julia

AU - Su, Jinpeng

AU - Steiger, Katja

AU - Michel, Marie Louise

AU - Protzer, Ulrike

AU - Knolle, Percy A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Therapeutic vaccination against chronic hepatitis B must overcome high viral antigen load and local regulatory mechanisms that promote immune-tolerance in the liver and curtail hepatitis B virus (HBV)-specific CD8 T cell immunity. Here, we report that therapeutic heterologous HBcore-protein-prime/Modified-Vaccinia-Virus-Ankara (MVA-HBcore) boost vaccination followed by CpG-application augmented vaccine-induced HBcAg-specific CD8 T cell-function in the liver. In HBV-transgenic as well as AAV-HBV-transduced mice with persistent high-level HBV-replication, the combination of therapeutic vaccination with subsequent CpG-application was synergistic to generate more potent HBV-specific CD8 T cell immunity that improved control of hepatocytes replicating HBV.

AB - Therapeutic vaccination against chronic hepatitis B must overcome high viral antigen load and local regulatory mechanisms that promote immune-tolerance in the liver and curtail hepatitis B virus (HBV)-specific CD8 T cell immunity. Here, we report that therapeutic heterologous HBcore-protein-prime/Modified-Vaccinia-Virus-Ankara (MVA-HBcore) boost vaccination followed by CpG-application augmented vaccine-induced HBcAg-specific CD8 T cell-function in the liver. In HBV-transgenic as well as AAV-HBV-transduced mice with persistent high-level HBV-replication, the combination of therapeutic vaccination with subsequent CpG-application was synergistic to generate more potent HBV-specific CD8 T cell immunity that improved control of hepatocytes replicating HBV.

UR - http://www.scopus.com/inward/record.url?scp=85070636941&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-47149-w

DO - 10.1038/s41598-019-47149-w

M3 - Article

C2 - 31346211

AN - SCOPUS:85070636941

VL - 9

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 10808

ER -

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection

Abstract

Access to Document

Other files and links

Fingerprint

Cite this